Memantin Basics

Memantine, the active ingredient in Memantin Basics, is an NMDA receptor antagonist presented as an oral formulation for oral use. It is employed in the symptomatic treatment of Alzheimer’s disease, helping to improve cognition and daily functioning in patients with mild to moderate disease.

GNH USA supplies Memantin Basics as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides regulatory documentation to support import and distribution across multiple regions.

Memantine is an NMDA receptor antagonist used in the management of neurodegenerative conditions, primarily Alzheimer’s disease.

Alzheimer’s disease (mild to moderate): improves cognition, functional abilities, and global clinical status in patients with symptomatic disease. Alzheimer’s disease (moderate to severe): provides symptomatic benefit and may slow functional decline in later stages of the disease.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Headache: mild to moderate intensity. - Constipation: reduced bowel movements. - Confusion: transient disorientation. - Somnolence: increased sleepiness.

Serious or Rare Side Effects: - Seizures: occurrence of convulsive episodes. - Cardiac arrhythmia: irregular heart rhythm. - Severe allergic reaction: rash, swelling, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or hepatitis.

Memantine should be used with caution in specific clinical situations. - Renal impairment: assess kidney function and consider dose adjustment. - Hepatic impairment: monitor liver enzymes regularly. - History of seizures: evaluate risk and monitor closely. - Concurrent use with other NMDA antagonists: avoid additive neurotoxicity. - Pregnancy: safety not established; use only if clearly needed. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Memantine may interact with several medications; monitoring is advised.

Major Interactions (Avoid): - Amantadine: combined NMDA antagonism may increase neurotoxicity. - Ketamine: additive CNS depression and severe psychomotor effects. - Other NMDA antagonists (e.g., dextromethorphan): avoid concurrent use.

Moderate Interactions (Monitor Closely): - Anticholinergic agents: may worsen cognitive side effects. - CNS depressants (e.g., benzodiazepines): may increase sedation. - Diuretics: may alter plasma concentrations of memantine.